"Because HCV treatment with a DAA regimen is well tolerated for nearly all patients, we believe these findings provide further support for universal HCV treatment coverage for all patients affected by HCV," Nguyen and colleagues write.
The strengths of this study are its large sample of DAA-treated and untreated patients from diverse racial and ethnic groups from across the United States and from diverse practice settings . One limitation is that the study cohort included only patients covered by private insurance; therefore, the findings may not be generalizable to individuals who are underinsured or not insured. Miscoding and misclassification are also possible with large claims databases.
Support for the study was provided by Stanford University and the Stanford Center for Population Health Sciences. Nguyen has received institutional grants and advisory board fees from Gilead Sciences outside the submitted work.